Brief: Cabaletta Bio Receives FDA Clearance Of CABA-201 IND Application For Treatment Of Generalized Myasthenia Gravis
06/11/2023 12:10
Nov 6 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA CLEARANCE OF CABA-201 IND
APPLICATION
FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
Source text for Eikon: ID:nGNX8RZ3H7
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview